https://2581150.fs1.hubspotusercontent-na1.net/hubfs/2581150/WNX%...

https://2581150.fs1.hubspotusercontent-na1.net/hubfs/2581150/WNX%20Research%20Update%20May%202024-1.pdf

An updated desk note with both revised price targets & financials on the previously released report

Whilst the total sales for the FY24' period has dropped from FY23' due to the delayed transaction with the acquisition of PainAway, gross margin %'s jumping from 17% in FY23' to 33.4% in FY24' show the immediacy of the impact that this transaction is having on the companies bottom line.

Key Points
- Gross profit projections for FY24' and beyond have gross margin %'s hovering at and above ~29%
- Sales tipped to grow to over $49m for the FY25' period, and then $78m for the FY26'
- Despite the delays in both the PainAway transaction + the regulatory bottleneck of ticking off its 8 OTC applications, the company achieved an operational profit for the February period, demonstrating the strength of the business and the benefit of having multiple revenue streams

Whilst these delays coupled with disgruntled existing holders have resulted in a depressed share price, it has created an attractive base level for new investors to invest at, with the company currently capped @ only ~$35m